Suraksha Diagnostic Limited has informed the Exchange regarding Outcome of Board Meeting held on May 21, 2026.
SURAKSHA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Suraksha Diagnostic reported strong annual results for FY2026 ending March 31. Standalone revenue grew 20.7% to ₹30,068 lakhs from ₹24,910 lakhs, while consolidated revenue rose 23.1% to ₹31,041 lakhs from ₹25,209 lakhs. Net profit after tax on standalone basis was ₹3,406 lakhs (EPS ₹6.54) vs ₹3,344 lakhs (EPS ₹6.42) in prior year. The Board recommended a maiden dividend of ₹0.50 per share (25% on ₹2 face value) for FY2026, subject to shareholder approval at the 21st AGM on September 2, 2026. Record date for dividend entitlement is August 26, 2026. The company expanded its network with new subsidiaries including Fetomat Wellness acquired in April 2025. Capital expenditure was significant at ₹5,012 lakhs. Statutory auditors MSKA & Associates gave an unmodified opinion on the financials.
Positive for shareholders - revenue growth of over 20%, maiden dividend declared, and clean audit opinion indicate healthy operations. The dividend yield at current market price appears modest but signals management confidence. Expansion through acquisition may support future growth.